PTHS

3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors interested in arranging one-on-one meetings should contact their Piper Sandler representative.About Pelthos TherapeuticsPelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos' Chief Financial Officer since July 2025. "John played a key role in helping us establish and launch Pelthos. He is an experienced financial leader, and we are excited to have him step into this new role as we continue our strong commercial momentum and enter the next phase of the company's growth," said Scott Plesha, CEO of

8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)

Cantor Fitzgerald initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $50.00

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos' subsidiary Channel Pharmaceutical Corporation ("Channel") owns the

8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

10-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025. Management will host a conference call today at 8:00 a.m. EDT DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmace

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time. Investors interested in arranging one-on-one meetings should contact their ROTH representative. A live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company's website at https://pelthos.com. A replay of the webcast will be available for 90 days following the event. Ab

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time. Details for the conference call can be found below: Date:Thursday, March 19, 2026Time: 8:00 a.m. Eastern TimeToll Free: 1-877-451-6152International:1-201-389-0879Conf.ID: 13758894  Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655  A